🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

25 recruiting trials

for Oligodendroglioma

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma NCT05512351Phase 21 site📍 Zhengzhou Henan Provincial People's Hospital · Tests: Tislelizumab plus Bevacizumab HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer) NCT06930846NA1 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: HOBSCOTCH-CA Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas NCT07468136Phase 1, Phase 21 site📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery NCT04702581Phase 326 sites📍 Amiens📍 Angers📍 Bordeaux Hospices Civils de Lyon · Tests: PCV chemotherapy, Radiotherapy and PCV chemotherapy All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma NCT05345002Phase 21 site📍 Philadelphia Stephen Bagley, MD, MSCE · Tests: Retifanlimab, All-trans retinoic acid FearLess in NeuroOncology NCT06989086NA1 site📍 Richmond Virginia Commonwealth University · Tests: Fearless in Neuro-Oncology A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma NCT05698524Phase 11 site📍 Omaha University of Nebraska · Tests: PCI 24781, Temozolomide Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis: NCT07608003n/a1 site📍 Changsha Xiangya Hospital of Central South University ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients NCT06254326Phase 11 site📍 Gainesville University of Florida · Tests: TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388Phase 13 sites📍 Birmingham📍 St Louis📍 Houston M.D. Anderson Cancer Center · Tests: G207 SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma NCT04923126Phase 1, Phase 21 site📍 Memphis St. Jude Children's Research Hospital · Tests: Mirdametinib Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. NCT07439172Phase 21 site📍 Camden The Cooper Health System · Tests: Pre-radiation temozolomide. A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). NCT05331521Phase 319 sites📍 Heidelberg📍 Berlin📍 Bochum University Hospital Heidelberg · Tests: CETEG, PCV, RT Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 NCT07462507Phase 21 site📍 St Louis Washington University School of Medicine · Tests: [C-11]-CS1P1, Brain MRI Implantable Microdevice In Primary Brain Tumors NCT04135807EARLY Phase 11 site📍 Boston Oliver Jonas · Tests: Microdevice Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation NCT07286292Phase 25 sites📍 Los Angeles📍 Chicago📍 Boston Institut de Recherches Internationales Servier (I.R.I.S.) · Tests: Vorasidenib Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas NCT04623931Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR) NCT07159607n/a2 sites📍 Vienna📍 Munich LMU Klinikum PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas NCT05190172NA1 site📍 Oslo Oslo University Hospital · Tests: Radiation therapy Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease NCT07703436Phase 212 sites📍 Los Angeles📍 San Francisco📍 New Haven Nuvation Bio Inc. · Tests: Safusidenib Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082Phase 11 site📍 Bethesda Jazz Pharmaceuticals · Tests: ONC206 SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) NCT05303519Phase 361 sites📍 Birmingham📍 Phoenix📍 Phoenix Nuvation Bio Inc. · Tests: safusidenib, Placebo Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age NCT05956821Phase 1, Phase 21 site📍 Miami University of Miami · Tests: SIACI of cetuximab and bevacizumab Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology NCT04648462n/a3 sites📍 Maastricht📍 Groningen📍 Delft Maastricht Radiation Oncology · Tests: ProTRAIT Study of Olutasidenib and Temozolomide in HGG NCT06161974Phase 220 sites📍 Aurora📍 Washington D.C.📍 Miami Rigel Pharmaceuticals · Tests: Olutasidenib + TMZ
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy